Overview

The goal of my research is to understand why certain patients respond positively to a medication, while others receive no benefit, or worse, develop debilitating or life-threatening adverse drug reactions(ADRs) to the same dose of medication. Individual patients respond differently to many medications because of small genetic differences that change the way a medication is metabolised.

By working collaboratively with clinicians and researchers from across Canada and around the world, we have recruited patients that have suffered specific serious ADRs, as well as control patients that have recived the same drugs without ADRs. We use high-throughput genomics and next-generation DNA sequencing technologies to identify the genetic factors of severe ADRs of key clinical importance.

The research involves many approaches from statistical, computational and molecular genetics, to molecular biology, and cell biology. The program’s mission is to translate these findings into new diagnostics that will improve the quality of lives of patients and families by preventing ADRs.

Publications

Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G > A and a large intragenic inversion in DPYD spanning intron 8 to intron 12.
Human mutation
van Kuilenburg ABP and Tarailo-Graovac M and Meijer J and Drogemoller B and Vockley J and Maurer D and Dobritzsch D and Ross CJ and Wasserman W and Meinsma R and Zoetekouw L and van Karnebeek CDM
DOI: 10.1002/humu.23538
PubMed: 29691939
04/2018

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research
Drögemöller BI and Brooks B and Critchley C and Monzon JG and Wright GEB and Liu G and Renouf DJ and Kollmannsberger CK and Bedard PL and Hayden MR and Gelmon KA and Carleton BC and Ross CJD
DOI: 10.1158/1078-0432.ccr-17-2810
PubMed: 29358504
04/2018

Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.
PM & R : the journal of injury, function, and rehabilitation
McLaughlin MJ and He Y and Brunstrom-Hernandez J and Thio LL and Carleton BC and Ross CJD and Gaedigk A and Lewandowski A and Dai H and Jusko WJ and Leeder JS
DOI: 10.1016/j.pmrj.2017.08.441
PubMed: 28867665
03/2018

Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome.
Journal of child neurology
Horvath GA and Tarailo-Graovac M and Bartel T and Race S and Van Allen MI and Blydt-Hansen I and Ross CJ and Wasserman WW and Connolly MB and van Karnebeek CDM
DOI: 10.1177/0883073817740443
PubMed: 29246092
01/2018

The genotypic and phenotypic spectrum of MTO1 deficiency.
Molecular genetics and metabolism
O'Byrne JJ and Tarailo-Graovac M and Ghani A and Champion M and Deshpande C and Dursun A and Ozgul RK and Freisinger P and Garber I and Haack TB and Horvath R and Baric I and Husain RA and van Karnebeek CDM
DOI: 10.1016/j.ymgme.2017.11.003
PubMed: 29331171
01/2018

Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.
Neurology
McCormack M and Gui H and Ingason A and Speed D and Wright GEB and Zhang EJ and Secolin R and Yasuda C and Kwok M and Wolking S and Becker F and Rau S and Avbersek A and Heggeli K and Leu C and Cavalleri GL
DOI: 10.1212/wnl.0000000000004853
PubMed: 29288229
01/2018

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
JAMA oncology
Drögemöller BI and Monzon JG and Bhavsar AP and Borrie AE and Brooks B and Wright GEB and Liu G and Renouf DJ and Kollmannsberger CK and Bedard PL and Aminkeng F and Amstutz U and Carleton BC
DOI: 10.1001/jamaoncol.2017.0502
PubMed: 28448657
11/2017

A de novo mosaic mutation in SPAST with two novel alternative alleles and chromosomal copy number variant in a boy with spastic paraplegia and autism spectrum disorder.
European journal of medical genetics
Matthews AM and Tarailo-Graovac M and Price EM and Blydt-Hansen I and Ghani A and Drögemöller BI and Robinson WP and Ross CJ and Wasserman WW and Siden H and van Karnebeek CD
DOI: 10.1016/j.ejmg.2017.07.015
PubMed: 28778789
10/2017

Exploring genetic influences underlying acute aerobic exercise effects on motor learning.
Scientific reports
Mang CS and McEwen LM and MacIsaac JL and Snow NJ and Campbell KL and Kobor MS and Ross CJD and Boyd LA
DOI: 10.1038/s41598-017-12422-3
PubMed: 28935933
09/2017

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
BMJ open
Kowalec K and Kingwell E and Carruthers R and Marrie RA and Bernatsky S and Traboulsee A and Ross CJD and Carleton B and Tremlett H
DOI: 10.1136/bmjopen-2017-016276
PubMed: 28576902
06/2017

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.
Genome medicine
Ross CJ and Towfic F and Shankar J and Laifenfeld D and Thoma M and Davis M and Weiner B and Kusko R and Zeskind B and Knappertz V and Grossman I and Hayden MR
DOI: 10.1186/s13073-017-0436-y
PubMed: 28569182
05/2017

A case of splenomegaly in CBL syndrome.
Coe RR and McKinnon ML and Tarailo-Graovac M and Ross CJ and Wasserman WW and Friedman JM and Rogers PC and van Karnebeek CDM
DOI: 10.1016/j.ejmg.2017.04.009
PubMed: 28414188
04/2017

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F and Ross CJ and Rassekh SR and Rieder MJ and Bhavsar AP and Sanatani S and Bernstein D and Hayden MR and Amstutz U and Carleton BC
DOI: 10.1111/bcp.13218
PubMed: 28317142
03/2017

A girl with developmental delay, ataxia, cranial nerve palsies, severe respiratory problems in infancy-Expanding NDST1 syndrome.
Armstrong L and Tarailo-Graovac M and Sinclair G and Seath KI and Wasserman WW and Ross CJ and van Karnebeek CD
DOI: 10.1002/ajmg.a.37621
PubMed: 28211985
03/2017

Identification of a large intronic transposal insertion in SLC17A5 causing sialic acid storage disease.
Tarailo-Graovac M and Drögemöller BI and Wasserman WW and Ross CJ and van den Ouweland AM and Darin N and Kollberg G and van Karnebeek CD and Blomqvist M
DOI: 10.1186/s13023-017-0584-6
PubMed: 28187749
02/2017

The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America.
Kay C and Tirado-Hurtado I and Cornejo-Olivas M and Collins JA and Wright G and Inca-Martinez M and Veliz-Otani D and Ketelaar ME and Slama RA and Ross CJ and Mazzetti P and Hayden MR
DOI: 10.1038/ejhg.2016.169
PubMed: 28000697
02/2017

Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
Bhavsar AP and Gunaretnam EP and Li Y and Hasbullah JS and Carleton BC and Ross CJ
DOI: 10.1371/journal.pone.0175711
PubMed: 28406961
2017

Mitochondrial Complex III Deficiency with Ketoacidosis and Hyperglycemia Mimicking Neonatal Diabetes.
Anastasio N and Tarailo-Graovac M and Al-Khalifah R and Legault L and Drogemoller B and Ross CJ and Wasserman WW and van Karnebeek C and Buhas D
DOI: 10.1007/8904_2016_557
PubMed: 27074787
2017

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.
McMahon KR and Rod Rassekh S and Schultz KR and Pinsk M and Blydt-Hansen T and Mammen C and Tsuyuki RT and Devarajan P and Cuvelier GD and Mitchell LG and Baruchel S and Palijan A and Carleton BC and Ross CJ and Zappitelli M and Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group
DOI: 10.1177/2054358117690338
PubMed: 28270931
2017

The global spectrum of protein-coding pharmacogenomic diversity.
Wright GE and Carleton B and Hayden MR and Ross CJ
DOI: 10.1038/tpj.2016.77
PubMed: 27779249
10/2016

Nuclear Receptor NR1H3 in Familial Multiple Sclerosis.
Wang Z and Sadovnick AD and Traboulsee AL and Ross JP and Bernales CQ and Encarnacion M and Yee IM and de Lemos M and Greenwood T and Lee JD and Wright G and Ross CJ and Zhang S and Song W and Vilariño-Güell C
DOI: 10.1016/j.neuron.2016.09.028
PubMed: 27764675
10/2016

Case-Control Studies Are Not Familial Studies.
Wang Z and Sadovnick AD and Traboulsee AL and Ross JP and Bernales CQ and Encarnacion M and Yee IM and de Lemos M and Greenwood T and Lee JD and Wright G and Ross CJ and Zhang S and Song W and Vilariño-Güell C
DOI: 10.1016/j.neuron.2016.09.053
PubMed: 27764669
10/2016

Editorial Note to:Nuclear Receptor NR1H3 in Familial Multiple Sclerosis.
Wang Z and Sadovnick AD and Traboulsee AL and Ross JP and Bernales CQ and Encarnacion M and Yee IM and de Lemos M and Greenwood T and Lee JD and Wright G and Ross CJ and Zhang S and Song W and Vilariño-Güell C
DOI: 10.1016/j.neuron.2016.10.008
PubMed: 27764666
10/2016

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F and Ross CJ and Rassekh SR and Hwang S and Rieder MJ and Bhavsar AP and Smith A and Sanatani S and Gelmon KA and Bernstein D and Hayden MR and Amstutz U and Carleton BC and CPNDS Clinical Practice Recommendations Group
DOI: 10.1111/bcp.13008
PubMed: 27197003
09/2016

A Tetra-Primer Amplification Refractory System Technique for the Cost-Effective and Novel Genotyping of Eight Single-Nucleotide Polymorphisms of the Catechol-O-Methyltransferase Gene.
Wang CK and Aleksic A and Xu MS and Procyshyn RM and Ross CJ and Vila-Rodriguez F and Ramos-Miguel A and Yan R and Honer WG and Barr AM
DOI: 10.1089/gtmb.2015.0304
PubMed: 27228319
08/2016

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
Lee JW and Pussegoda K and Rassekh SR and Monzon JG and Liu G and Hwang S and Bhavsar AP and Pritchard S and Ross CJ and Amstutz U and Carleton BC and CPNDS Clinical Recommendations Group
DOI: 10.1097/ftd.0000000000000298
PubMed: 26960170
08/2016

NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
van Karnebeek CD and Bonafé L and Wen XY and Tarailo-Graovac M and Balzano S and Royer-Bertrand B and Ashikov A and Garavelli L and Mammi I and Turolla L and Breen C and Donnai D and Cormier V and Heron D and Nishimura G and Uchikawa S and Campos-Xavier B and Rossi A and Hennet T and Brand-Arzamendi K
DOI: 10.1038/ng.3578
PubMed: 27213289
07/2016

Nuclear Receptor NR1H3 in Familial Multiple Sclerosis.
Wang Z and Sadovnick AD and Traboulsee AL and Ross JP and Bernales CQ and Encarnacion M and Yee IM and de Lemos M and Greenwood T and Lee JD and Wright G and Ross CJ and Zhang S and Song W and Vilariño-Güell C
DOI: 10.1016/j.neuron.2016.04.039
PubMed: 27253448
06/2016

De novo dominant variants affecting the motor domain of KIF1A are a cause of PEHO syndrome.
Langlois S and Tarailo-Graovac M and Sayson B and Drögemöller B and Swenerton A and Ross CJ and Wasserman WW and van Karnebeek CD
DOI: 10.1038/ejhg.2015.217
PubMed: 26486474
06/2016

Exome Sequencing and the Management of Neurometabolic Disorders.
Tarailo-Graovac M and Shyr C and Ross CJ and Horvath GA and Salvarinova R and Ye XC and Zhang LH and Bhavsar AP and Lee JJ and Drögemöller BI and Abdelsayed M and Alfadhel M and Armstrong L and Baumgartner MR and Burda P and Connolly MB and Cameron J and Demos M and Dewan T and Dionne J
DOI: 10.1056/nejmoa1515792
PubMed: 27276562
06/2016

Cytosolic phosphoenolpyruvate carboxykinase deficiency presenting with acute liver failure following gastroenteritis.
Santra S and Cameron JM and Shyr C and Zhang L and Drögemöller B and Ross CJ and Wasserman WW and Wevers RA and Rodenburg RJ and Gupte G and Preece MA and van Karnebeek CD
DOI: 10.1016/j.ymgme.2016.03.001
PubMed: 26971250
05/2016

Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
Cohen AS and Yap DB and Lewis ME and Chijiwa C and Ramos-Arroyo MA and Tkachenko N and Milano V and Fradin M and McKinnon ML and Townsend KN and Xu J and Van Allen MI and Ross CJ and Dobyns WB and Weaver DD and Gibson WT
DOI: 10.1002/humu.22946
PubMed: 26694085
03/2016

Forensic Investigation of Methadone Concentrations in Deceased Breastfed Infants.
Madadi P and Kelly LE and Ross CJ and Kepron C and Edwards JN and Koren G
DOI: 10.1111/1556-4029.12972
PubMed: 26513313
03/2016

Secondary neurotransmitter deficiencies in epilepsy caused by voltage-gated sodium channelopathies: A potential treatment target?
Horvath GA and Demos M and Shyr C and Matthews A and Zhang L and Race S and Stockler-Ipsiroglu S and Van Allen MI and Mancarci O and Toker L and Pavlidis P and Ross CJ and Wasserman WW and Trump N and Heales S and Pope S and Cross JH and van Karnebeek CD
DOI: 10.1016/j.ymgme.2015.11.008
PubMed: 26647175
01/2016

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics.
Chan SL and Samaranayake N and Ross CJ and Toh MT and Carleton B and Hayden MR and Teo YY and Dissanayake VH and Brunham LR
DOI: 10.1097/fpc.0000000000000182
PubMed: 26444257
01/2016

Further Validation of the SIGMAR1 c.151+1G>T Mutation as Cause of Distal Hereditary Motor Neuropathy.
Child neurology open
Lee JJY and van Karnebeek CDM and Drögemoller B and Shyr C and Tarailo-Graovac M and Eydoux P and Ross CJ and Wasserman WW and Björnson B and Wu JK
DOI: 10.1177/2329048x16669912
PubMed: 28503617
2016

Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.
Kay C and Collins JA and Skotte NH and Southwell AL and Warby SC and Caron NS and Doty CN and Nguyen B and Griguoli A and Ross CJ and Squitieri F and Hayden MR
DOI: 10.1038/mt.2015.128
PubMed: 26201449
11/2015

RMND1 deficiency associated with neonatal lactic acidosis, infantile onset renal failure, deafness, and multiorgan involvement.
Janer A and van Karnebeek CD and Sasarman F and Antonicka H and Al Ghamdi M and Shyr C and Dunbar M and Stockler-Ispiroglu S and Ross CJ and Vallance H and Dionne J and Wasserman WW and Shoubridge EA
DOI: 10.1038/ejhg.2014.293
PubMed: 25604853
10/2015

The pharmacogenetics of codeine pain relief in the postpartum period.
Baber M and Chaudhry S and Kelly L and Ross C and Carleton B and Berger H and Koren G
DOI: 10.1038/tpj.2015.3
PubMed: 25752520
10/2015

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F and Bhavsar AP and Visscher H and Rassekh SR and Li Y and Lee JW and Brunham LR and Caron HN and van Dalen EC and Kremer LC and van der Pal HJ and Amstutz U and Rieder MJ and Bernstein D and Carleton BC and Hayden MR and Ross CJ and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1038/ng.3374
PubMed: 26237429
09/2015

Development of a cost-efficient novel method for rapid, concurrent genotyping of five common single nucleotide polymorphisms of the brain derived neurotrophic factor (BDNF) gene by tetra-primer amplification refractory mutation system.
Wang CK and Xu MS and Ross CJ and Lo R and Procyshyn RM and Vila-Rodriguez F and White RF and Honer WG and Barr AM
DOI: 10.1002/mpr.1475
PubMed: 26118823
09/2015

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.
Shaw K and Amstutz U and Kim RB and Lesko LJ and Turgeon J and Michaud V and Hwang S and Ito S and Ross C and Carleton BC and CPNDS Clinical Recommendation Group
DOI: 10.1097/ftd.0000000000000192
PubMed: 26186657
08/2015

Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
Jiménez-Triana CA and Castelán-Martínez OD and Rivas-Ruiz R and Jiménez-Méndez R and Medina A and Clark P and Rassekh R and Castañeda-Hernández G and Carleton B and Medeiros M and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1097/md.0000000000001413
PubMed: 26313789
08/2015

Genetic determinants of cocaine-associated agranulocytosis.
Buxton JA and Omura J and Kuo M and Ross C and Tzemis D and Purssell R and Gardy J and Carleton B
DOI: 10.1186/s13104-015-1219-4
PubMed: 26070312
06/2015

Association between regulatory advisories and codeine prescribing to postpartum women.
Smolina K and Weymann D and Morgan S and Ross C and Carleton B
DOI: 10.1001/jama.2015.3642
PubMed: 25965237
05/2015

Expansion of the QARS deficiency phenotype with report of a family with isolated supratentorial brain abnormalities.
Salvarinova R and Ye CX and Rossi A and Biancheri R and Roland EH and Pavlidis P and Ross CJ and Tarailo-Graovac M and Wasserman WW and van Karnebeek CD
DOI: 10.1007/s10048-014-0432-y
PubMed: 25432320
04/2015

Defects in fatty acid amide hydrolase 2 in a male with neurologic and psychiatric symptoms.
Sirrs S and van Karnebeek CD and Peng X and Shyr C and Tarailo-Graovac M and Mandal R and Testa D and Dubin D and Carbonetti G and Glynn SE and Sayson B and Robinson WP and Han B and Wishart D and Ross CJ and Wasserman WW and Hurwitz TA and Sinclair G and Kaczocha M
DOI: 10.1186/s13023-015-0248-3
PubMed: 25885783
03/2015

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Visscher H and Rassekh SR and Sandor GS and Caron HN and van Dalen EC and Kremer LC and van der Pal HJ and Rogers PC and Rieder MJ and Carleton BC and Hayden MR and Ross CJ and CPNDS consortium
DOI: 10.2217/pgs.15.61
PubMed: 26230641
2015

The genotypic and phenotypic spectrum of PIGA deficiency.
Tarailo-Graovac M and Sinclair G and Stockler-Ipsiroglu S and Van Allen M and Rozmus J and Shyr C and Biancheri R and Oh T and Sayson B and Lafek M and Ross CJ and Robinson WP and Wasserman WW and Rossi A and van Karnebeek CD
DOI: 10.1186/s13023-015-0243-8
PubMed: 25885527
2015

Use of pharmacogenomics in pediatric renal transplant recipients.
Medeiros M and Castañeda-Hernández G and Ross CJ and Carleton BC
DOI: 10.3389/fgene.2015.00041
PubMed: 25741362
2015

A single bout of high-intensity aerobic exercise facilitates response to paired associative stimulation and promotes sequence-specific implicit motor learning.
Mang CS and Snow NJ and Campbell KL and Ross CJ and Boyd LA
DOI: 10.1152/japplphysiol.00498.2014
PubMed: 25257866
12/2014

Pharmacogenomic diversity in Singaporean populations and Europeans.
Brunham LR and Chan SL and Li R and Aminkeng F and Liu X and Saw WY and Ong RT and Pillai EN and Carleton BC and Toh D and Tan SH and Koo SH and Lee EJ and Chia KS and Ross CJ and Hayden MR and Sung C and Teo YY
DOI: 10.1038/tpj.2014.22
PubMed: 24861855
12/2014

Single point mutation in Rabenosyn-5 in a female with intractable seizures and evidence of defective endocytotic trafficking.
Stockler S and Corvera S and Lambright D and Fogarty K and Nosova E and Leonard D and Steinfeld R and Ackerley C and Shyr C and Au N and Selby K and van Allen M and Vallance H and Wevers R and Watkins D and Rosenblatt D and Ross CJ and Conibear E and Wasserman W and van Karnebeek C
DOI: 10.1186/s13023-014-0141-5
PubMed: 25233840
09/2014

Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD and Jiménez-Méndez R and Rodríguez-Islas F and Fierro-Evans M and Vázquez-Gómez BE and Medina-Sansón A and Clark P and Carleton B and Ross C and Hildebrand C and Castañeda-Hernández G and Rivas-Ruiz R
DOI: 10.1016/j.ijporl.2014.06.007
PubMed: 25037447
09/2014

Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC and Ross CJ and Pussegoda K and Bhavsar AP and Visscher H and Lee JW and Brooks B and Rassekh SR and Dubé MP and Hayden MR
DOI: 10.1038/clpt.2014.92
PubMed: 25141953
09/2014

AIMP1 deficiency presents as a cortical neurodegenerative disease with infantile onset.
Armstrong L and Biancheri R and Shyr C and Rossi A and Sinclair G and Ross CJ and Tarailo-Graovac M and Wasserman WW and van Karnebeek CD
DOI: 10.1007/s10048-014-0411-3
PubMed: 24958424
08/2014

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
Carleton BC and Ross CJ and Bhavsar AP and Lee JW and Visscher H and Rassekh SR and Hayden MR
DOI: 10.1038/clpt.2014.90
PubMed: 24755913
08/2014

The emerging era of pharmacogenomics: current successes, future potential, and challenges.
Lee JW and Aminkeng F and Bhavsar AP and Shaw K and Carleton BC and Hayden MR and Ross CJ
DOI: 10.1111/cge.12392
PubMed: 24684508
07/2014

Codeine-related deaths: The role of pharmacogenetics and drug interactions.
Lam J and Woodall KL and Solbeck P and Ross CJ and Carleton BC and Hayden MR and Koren G and Madadi P
DOI: 10.1016/j.forsciint.2014.03.018
PubMed: 24747667
06/2014

Development of a broad-based ADME panel for use in pharmacogenomic studies.
Brown AM and Renaud Y and Ross C and Hansen M and Mongrain I and Valois D and Carleton BC and Hayden MR and Dubé MP and Tardif JC and Phillips MS
DOI: 10.2217/pgs.14.81
PubMed: 25141894
06/2014

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K and Amstutz U and Hildebrand C and Rassekh SR and Hosking M and Neville K and Leeder JS and Hayden MR and Ross CJ and Carleton BC
DOI: 10.1002/pbc.24932
PubMed: 24474498
06/2014

DNAJC13 mutations in Parkinson disease.
Vilariño-Güell C and Rajput A and Milnerwood AJ and Shah B and Szu-Tu C and Trinh J and Yu I and Encarnacion M and Munsie LN and Tapia L and Gustavsson EK and Chou P and Tatarnikov I and Evans DM and Pishotta FT and Volta M and Beccano-Kelly D and Thompson C and Lin MK and Sherman HE
DOI: 10.1093/hmg/ddt570
PubMed: 24218364
04/2014

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.
Aminkeng F and Ross CJ and Rassekh SR and Brunham LR and Sistonen J and Dube MP and Ibrahim M and Nyambo TB and Omar SA and Froment A and Bodo JM and Tishkoff S and Carleton BC and Hayden MR and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1038/tpj.2013.13
PubMed: 23588107
04/2014

Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood.
van Karnebeek CD and Sly WS and Ross CJ and Salvarinova R and Yaplito-Lee J and Santra S and Shyr C and Horvath GA and Eydoux P and Lehman AM and Bernard V and Newlove T and Ukpeh H and Chakrapani A and Preece MA and Ball S and Pitt J and Vallance HD and Coulter-Mackie M and Nguyen H
DOI: 10.1016/j.ajhg.2014.01.006
PubMed: 24530203
03/2014

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC and Ross CJ and Bhavsar AP and Amstutz U and Pussegoda K and Visscher H and Lee JW and Brooks B and Rassekh SR and Dubé MP and Hayden MR
DOI: 10.1038/clpt.2013.219
PubMed: 24193170
03/2014

A novel recurrent mutation in ATP1A3 causes CAPOS syndrome.
Demos MK and van Karnebeek CD and Ross CJ and Adam S and Shen Y and Zhan SH and Shyr C and Horvath G and Suri M and Fryer A and Jones SJ and Friedman JM and FORGE Canada Consortium
DOI: 10.1186/1750-1172-9-15
PubMed: 24468074
01/2014

Exome sequencing pilot study in children with carbamazepine-induced serious skin reactions.
Amstutz U and Shyr C and Shear NH and Rieder MJ and Wasserman WW and Ross CJ and Carleton BC
DOI: 10.1186/2045-7022-4-s3-p119
2014

Promoting neuroplasticity for motor rehabilitation after stroke: considering the effects of aerobic exercise and genetic variation on brain-derived neurotrophic factor.
Mang CS and Campbell KL and Ross CJ and Boyd LA
DOI: 10.2522/ptj.20130053
PubMed: 23907078
12/2013

Instructor comfort level in high-fidelity simulation.
Harder BN and Ross CJ and Paul P
DOI: 10.1016/j.nedt.2012.09.003
PubMed: 23025906
10/2013

Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers.
Lam J and Kelly L and Matok I and Ross CJ and Carleton BC and Hayden MR and Madadi P and Koren G
DOI: 10.1097/ftd.0b013e318288f158
PubMed: 23783165
08/2013

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H and Ross CJ and Rassekh SR and Sandor GS and Caron HN and van Dalen EC and Kremer LC and van der Pal HJ and Rogers PC and Rieder MJ and Carleton BC and Hayden MR and CPNDS Consortium
DOI: 10.1002/pbc.24505
PubMed: 23441093
08/2013

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Pussegoda K and Ross CJ and Visscher H and Yazdanpanah M and Brooks B and Rassekh SR and Zada YF and Dubé MP and Carleton BC and Hayden MR and CPNDS Consortium
DOI: 10.1038/clpt.2013.80
PubMed: 23588304
08/2013

HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.
Amstutz U and Ross CJ and Castro-Pastrana LI and Rieder MJ and Shear NH and Hayden MR and Carleton BC and CPNDS Consortium
DOI: 10.1038/clpt.2013.55
PubMed: 23588310
07/2013

From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world.
Kastelein JJ and Ross CJ and Hayden MR
DOI: 10.1089/hum.2013.063
PubMed: 23578007
05/2013

Cancer pharmacogenomics in children: research initiatives and progress to date.
Rassekh SR and Ross CJ and Carleton BC and Hayden MR
DOI: 10.1007/s40272-013-0021-9
PubMed: 23529868
04/2013

Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.
Madadi P and Amstutz U and Rieder M and Ito S and Fung V and Hwang S and Turgeon J and Michaud V and Koren G and Carleton BC and CPNDS Clinical Recommendations Group
PubMed: 24214521
2013

A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk.
Kelly LE and Chaudhry SA and Rieder MJ and 't Jong G and Moretti ME and Lausman A and Ross C and Berger H and Carleton B and Hayden MR and Madadi P and Koren G
DOI: 10.1371/journal.pone.0070073
PubMed: 23922910
2013

The Salmonella type III effector SspH2 specifically exploits the NLR co-chaperone activity of SGT1 to subvert immunity.
Bhavsar AP and Brown NF and Stoepel J and Wiermer M and Martin DD and Hsu KJ and Imami K and Ross CJ and Hayden MR and Foster LJ and Li X and Hieter P and Finlay BB
DOI: 10.1371/journal.ppat.1003518
PubMed: 23935490
2013

Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT.
Shaw K and Amstutz U and Castro-Pastrana L and Loo TT and Ross CJ and Ito S and Reider MJ and Maher M and Macleod S and Koren G and Hayden MR and Carleton BC
PubMed: 23824325
2013

Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?
Madadi P and Sistonen J and Silverman G and Gladdy R and Ross CJ and Carleton BC and Carvalho JC and Hayden MR and Koren G
DOI: 10.1155/2013/518012
PubMed: 23748253
2013

Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study.
Khetani JD and Madadi P and Sommer DD and Reddy D and Sistonen J and Ross CJ and Carleton BC and Hayden MR and Koren G
DOI: 10.1007/bf03262421
PubMed: 23013460
12/2012

Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: the devil is in the details.
Lam J and Matlow JN and Ross CJ and Hayden MR and Carleton BC and Madadi P
DOI: 10.1097/ftd.0b013e31825da19f
PubMed: 22777151
08/2012

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR and Lansberg PJ and Zhang L and Miao F and Carter C and Hovingh GK and Visscher H and Jukema JW and Stalenhoef AF and Ross CJ and Carleton BC and Kastelein JJ and Hayden MR
DOI: 10.1038/tpj.2010.92
PubMed: 21243006
06/2012

Economic impact of a genetic test for cisplatin-induced ototoxicity.
Dionne F and Mitton C and Rassekh R and Brooks B and Ross C and Hayden M and Carleton B
DOI: 10.1038/tpj.2011.15
PubMed: 21502965
06/2012

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H and Ross CJ and Rassekh SR and Barhdadi A and Dubé MP and Al-Saloos H and Sandor GS and Caron HN and van Dalen EC and Kremer LC and van der Pal HJ and Brown AM and Rogers PC and Phillips MS and Rieder MJ and Carleton BC and Hayden MR and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1200/jco.2010.34.3467
PubMed: 21900104
05/2012

More codeine fatalities after tonsillectomy in North American children.
Kelly LE and Rieder M and van den Anker J and Malkin B and Ross C and Neely MN and Carleton B and Hayden MR and Madadi P and Koren G
DOI: 10.1542/peds.2011-2538
PubMed: 22492761
05/2012

Suspected opioid overdose case resolved by CYP2D6 genotyping.
Shaw KD and Amstutz U and Jimenez-Mendez R and Ross CJ and Carleton BC
DOI: 10.1097/ftd.0b013e31824a1e21
PubMed: 22406651
04/2012

Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.
Sistonen J and Madadi P and Ross CJ and Yazdanpanah M and Lee JW and Landsmeer ML and Nauta M and Carleton BC and Koren G and Hayden MR
DOI: 10.1038/clpt.2011.280
PubMed: 22398969
04/2012

Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
Visscher H and Amstutz U and Sistonen J and Ross CJ and Hayden MR and Carleton BC
DOI: 10.1097/fjc.0b013e3182163b82
PubMed: 21386709
09/2011

CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S and Berger H and Sistonen J and Madadi P and Matok I and Gijsen VM and de Wildt SN and Taddio A and Ross CJ and Carleton BC and Hayden MR and Koren G
DOI: 10.1097/ftd.0b013e3182272b10
PubMed: 21743374
08/2011

HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia.
Warby SC and Visscher H and Collins JA and Doty CN and Carter C and Butland SL and Hayden AR and Kanazawa I and Ross CJ and Hayden MR
DOI: 10.1038/ejhg.2010.229
PubMed: 21248742
05/2011

Amelioration of hypertriglyceridemia with hypo-alpha-cholesterolemia in LPL deficient mice by hematopoietic cell-derived LPL.
Ding Y and Zhang L and Wang Y and Huang W and Tang Y and Bai L and Ross CJ and Hayden MR and Liu G
DOI: 10.1371/journal.pone.0025620
PubMed: 21980507
2011

Pharmacogenomics of serious adverse drug reactions in pediatric oncology.
Ross CJ and Visscher H and Rassekh SR and Castro-Pastrana LI and Shereck E and Carleton B and Hayden MR
PubMed: 21467604
2011

Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits.
Madadi P and Joly Y and Avard D and Chitayat DC and Smith MA and Ross CJ and Carleton BC and Hayden MR and Koren G
DOI: 10.1038/clpt.2010.125
PubMed: 20739920
12/2010

Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.
Madadi P and Hildebrandt D and Gong IY and Schwarz UI and Ciszkowski C and Ross CJ and Sistonen J and Carleton BC and Hayden MR and Lauwers AE and Koren G
DOI: 10.1542/peds.2009-1907
PubMed: 20837591
10/2010

Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Loo TT and Ross CJ and Sistonen J and Visscher H and Madadi P and Koren G and Hayden MR and Carleton BC
DOI: 10.2217/pgs.10.111
PubMed: 20860467
09/2010

Ultrasound-guided sacroiliac joint injection in patients with established sacroiliitis: precise IA injection verified by MRI scanning does not predict clinical outcome.
Hartung W and Ross CJ and Straub R and Feuerbach S and Schölmerich J and Fleck M and Herold T
DOI: 10.1093/rheumatology/kep424
PubMed: 20019067
08/2010

The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
Ross CJ and Visscher H and Sistonen J and Brunham LR and Pussegoda K and Loo TT and Rieder MJ and Koren G and Carleton BC and Hayden MR and CPNDS Consortium
DOI: 10.1089/thy.2010.1642
PubMed: 20578893
07/2010

The importance of XRCC2 in RAD51-related DNA damage repair.
Tambini CE and Spink KG and Ross CJ and Hill MA and Thacker J
DOI: 10.1016/j.dnarep.2010.01.016
PubMed: 20189471
05/2010

Perceptions about self-management among people with severe asthma.
Ross CJ and Williams BA and Low G and Vethanayagam D
DOI: 10.3109/02770901003611462
PubMed: 20394519
04/2010

Cases: Cocaine adulterant linked to neutropenia.
Wiens MO and Son WK and Ross C and Hayden M and Carleton B
DOI: 10.1503/cmaj.090286
PubMed: 19969562
01/2010

Characterization of microvascularization of liver tumor lesions with high resolution linear ultrasound and contrast enhanced ultrasound (CEUS) during surgery: First results.
Jung EM and Ross CJ and Rennert J and Scherer MN and Farkas S and von Breitenbuch P and Schnitzbauer AA and Piso P and Lamby P and Menzel C and Schreyer AG and Feuerbach S and Schlitt HJ and Loss M
DOI: 10.3233/ch-2010-1336
PubMed: 21135485
2010

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ and Katzov-Eckert H and Dubé MP and Brooks B and Rassekh SR and Barhdadi A and Feroz-Zada Y and Visscher H and Brown AM and Rieder MJ and Rogers PC and Phillips MS and Carleton BC and Hayden MR and CPNDS Consortium
DOI: 10.1038/ng.478
PubMed: 19898482
12/2009

Application of principal component analysis to pharmacogenomic studies in Canada.
Visscher H and Ross CJ and Dubé MP and Brown AM and Phillips MS and Carleton BC and Hayden MR
DOI: 10.1038/tpj.2009.36
PubMed: 19652663
12/2009

Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
Carleton B and Poole R and Smith M and Leeder J and Ghannadan R and Ross C and Phillips M and Hayden M
DOI: 10.1002/pds.1772
PubMed: 19507171
08/2009

Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.
Vaessen SF and Dallinga-Thie GM and Ross CJ and Splint LJ and Castellani LW and Rensen PC and Hayden MR and Schaap FG and Kuivenhoven JA
DOI: 10.1194/jlr.m800551-jlr200
PubMed: 19141870
05/2009

Presynaptic defects underlying impaired learning and memory function in lipoprotein lipase-deficient mice.
Xian X and Liu T and Yu J and Wang Y and Miao Y and Zhang J and Yu Y and Ross C and Karasinska JM and Hayden MR and Liu G and Chui D
DOI: 10.1523/jneurosci.0297-09.2009
PubMed: 19357293
04/2009

Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells.
Wang Y and Sternfeld L and Yang F and Rodriguez JA and Ross C and Hayden MR and Carriere F and Liu G and Hofer W and Schulz I
DOI: 10.1136/gut.2007.146258
PubMed: 18936103
03/2009

Acute hypertriglyceridemic pancreatitis during pregnancy due to homozygous lipoprotein lipase gene mutation.
Bartha I and Dinya T and Seres I and Paragh G and Ross C and Hayden MR and Biró S and Vargha G
DOI: 10.1016/j.cca.2008.10.016
PubMed: 19000906
02/2009

Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.
Madadi P and Ross CJ and Hayden MR and Carleton BC and Gaedigk A and Leeder JS and Koren G
DOI: 10.1038/clpt.2008.157
PubMed: 18719619
01/2009

The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice.
Yang F and Wang Y and Sternfeld L and Rodriguez JA and Ross C and Hayden MR and Carriere F and Liu G and Schulz I
DOI: 10.1111/j.1748-1716.2008.01933.x
PubMed: 18983441
01/2009

Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safety.
Wong E and Carleton BC and Wright DF and Smith MA and Verbeek L and Hildebrand CA and Stannard P and Vaillancourt R and Elliot-Miller P and Ross CJ and Hayden MR
PubMed: 19380938
2009

Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.
Stroes ES and Nierman MC and Meulenberg JJ and Franssen R and Twisk J and Henny CP and Maas MM and Zwinderman AH and Ross C and Aronica E and High KA and Levi MM and Hayden MR and Kastelein JJ and Kuivenhoven JA
DOI: 10.1161/atvbaha.108.175620
PubMed: 18802015
12/2008

Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet.
Zhang X and Qi R and Xian X and Yang F and Blackstein M and Deng X and Fan J and Ross C and Karasinska J and Hayden MR and Liu G
DOI: 10.1161/circresaha.107.156554
PubMed: 18032735
02/2008

Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.
Oberlander TF and Bonaguro RJ and Misri S and Papsdorf M and Ross CJ and Simpson EM
DOI: 10.1038/sj.mp.4002007
PubMed: 17519929
01/2008

Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children.
Ross CJ and Carleton B and Warn DG and Stenton SB and Rassekh SR and Hayden MR
DOI: 10.1196/annals.1423.020
PubMed: 17911433
09/2007

Screening and assessing adolescent asthmatics for anxiety disorders.
Ross CJ and Davis TM and Hogg DY
DOI: 10.1177/1054773806295235
PubMed: 17204805
02/2007

Expression of LPL in endothelial-intact artery results in lipid deposition and vascular cell adhesion molecule-1 upregulation in both LPL and ApoE-deficient mice.
Wang J and Xian X and Huang W and Chen L and Wu L and Zhu Y and Fan J and Ross C and Hayden MR and Liu G
DOI: 10.1161/01.atv.0000249683.80414.d9
PubMed: 17038632
01/2007

Pharmacogenomics and its implications for autoimmune disease.
Ross CJ and Katzov H and Carleton B and Hayden MR
DOI: 10.1016/j.jaut.2007.02.008
PubMed: 17418528
2007

Volumetric cartilage measurements of porcine knee at 1.5-T and 3.0-T MR imaging: evaluation of precision and accuracy.
Bauer JS and Krause SJ and Ross CJ and Krug R and Carballido-Gamio J and Ozhinsky E and Majumdar S and Link TM
DOI: 10.1148/radiol.2412051330
PubMed: 17057067
11/2006

Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma.
Burgess BL and McIsaac SA and Naus KE and Chan JY and Tansley GH and Yang J and Miao F and Ross CJ and van Eck M and Hayden MR and van Nostrand W and St George-Hyslop P and Westaway D and Wellington CL
DOI: 10.1016/j.nbd.2006.06.007
PubMed: 16899370
10/2006

Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation.
Rip J and Nierman MC and Ross CJ and Jukema JW and Hayden MR and Kastelein JJ and Stroes ES and Kuivenhoven JA
DOI: 10.1161/01.atv.0000219283.10832.43
PubMed: 16574898
06/2006

Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.
Ross CJ and Twisk J and Bakker AC and Miao F and Verbart D and Rip J and Godbey T and Dijkhuizen P and Hermens WT and Kastelein JJ and Kuivenhoven JA and Meulenberg JM and Hayden MR
DOI: 10.1089/hum.2006.17.487
PubMed: 16716106
05/2006

Hemorheological abnormalities in lipoprotein lipase deficient mice with severe hypertriglyceridemia.
Zhao T and Guo J and Li H and Huang W and Xian X and Ross CJ and Hayden MR and Wen Z and Liu G
DOI: 10.1016/j.bbrc.2006.01.067
PubMed: 16460682
03/2006

Gene therapy for lipoprotein lipase deficiency: working toward clinical application.
Rip J and Nierman MC and Sierts JA and Petersen W and Van den Oever K and Van Raalte D and Ross CJ and Hayden MR and Bakker AC and Dijkhuizen P and Hermens WT and Twisk J and Stroes E and Kastelein JJ and Kuivenhoven JA and Meulenberg JM
DOI: 10.1089/hum.2005.16.1276
PubMed: 16259561
11/2005

Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation.
Ross CJ and Liu G and Kuivenhoven JA and Twisk J and Rip J and van Dop W and Excoffon KJ and Lewis SM and Kastelein JJ and Hayden MR
DOI: 10.1161/01.atv.0000176971.27302.b0
PubMed: 16002740
10/2005

Cognitive-behavioral treatment combined with asthma education for adults with asthma and coexisting panic disorder.
Ross CJ and Davis TM and MacDonald GF
DOI: 10.1177/1054773804273863
PubMed: 15793272
05/2005

Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.
Ross CJ and Twisk J and Meulenberg JM and Liu G and van den Oever K and Moraal E and Hermens WT and Rip J and Kastelein JJ and Kuivenhoven JA and Hayden MR
DOI: 10.1089/hum.2004.15.906
PubMed: 15353045
09/2004

Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1.
Wellington CL and Brunham LR and Zhou S and Singaraja RR and Visscher H and Gelfer A and Ross C and James E and Liu G and Huber MT and Yang YZ and Parks RJ and Groen A and Fruchart-Najib J and Hayden MR
DOI: 10.1194/jlr.m300110-jlr200
PubMed: 12730295
08/2003

A case study of comorbidities: vocal cord dysfunction, asthma, and panic disorder.
Heffern WA and Davis TM and Ross CJ
DOI: 10.1177/10573802011003007
PubMed: 12180643
08/2002

Screening and assessing adult asthmatics for anxiety disorders.
Davis TM and Ross CJ and MacDonald GF
DOI: 10.1177/105477380201100206
PubMed: 11991171
05/2002

Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics.
Van Raamsdonk JM and Ross CJ and Potter MA and Kurachi S and Kurachi K and Stafford DW and Chang PL
DOI: 10.1067/mlc.2002.120649
PubMed: 11873243
01/2002

Development of small alginate microcapsules for recombinant gene product delivery to the rodent brain.
Ross CJ and Chang PL
DOI: 10.1163/156856202320401988
PubMed: 12463513
2002

Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells.
Ross CJ and Ralph M and Chang PL
DOI: 10.1006/exnr.2000.7531
PubMed: 11085893
12/2000

Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells.
Ross CJ and Bastedo L and Maier SA and Sands MS and Chang PL
DOI: 10.1089/104303400750001426
PubMed: 11044913
10/2000

Delivery of recombinant gene products to the central nervous system with nonautologous cells in alginate microcapsules.
Ross CJ and Ralph M and Chang PL
DOI: 10.1089/10430349950019183
PubMed: 10022530
01/1999

Encapsulation of various recombinant mammalian cell types in different alginate microcapsules.
Peirone M and Ross CJ and Hortelano G and Brash JL and Chang PL
DOI: 10.1002/(sici)1097-4636(19981215)42:43.0.co;2-x
PubMed: 9827683
12/1998

A sequence-ready physical map of a region of 12q24.1.
Renault B and Hovnanian A and Bryce S and Chang JJ and Lau S and Sakuntabhai A and Monk S and Carter S and Ross CJ and Pang J and Twells R and Chamberlain S and Monaco AP and Strachan T and Kucherlapati R
DOI: 10.1006/geno.1997.4888
PubMed: 9344649
10/1997

Informational coping styles: a validity study.
Ross CJ and Maguire TO
PubMed: 8935771
1995

Comparisons of pulmonary artery pressure measurements in supine and 30 degree lateral positions.
Ross CJ and Jones R
PubMed: 8573278
1995

Hawaii Asian-American response to the Staying Healthy After Fifty program.
Roberts E and Takenaka JI and Ross CJ and Chong EH and Tulang JI and Napps SE
PubMed: 2621109
1989

Treatment issues in child abuse.
Ross CJ and Zigler E
PubMed: 6400728
05/1983

Of children and liberty: an historian's view.
Ross CJ
PubMed: 7114175
07/1982

Project head start.
Valentine J and Ross CJ and Zigler E
PubMed: 7389433
1980

Age and alcoholism.
Warder J and Ross CJ
PubMed: 5283827
06/1971

Blood culture in the diagnosis of leptospirosis in North Queensland.
ROSS CJ
PubMed: 13264862
08/1955

The investigation of fevers in North Queensland by mouse inoculation, with particular reference to scrub typhus.
CARLEY JG and DOHERTY RL and DERRICK EH and POPE JH and EMANUEL ML and ROSS CJ
PubMed: 13239522
05/1955

The serological classification of 89 strains of Leptospirae from North Queensland, including five serotypes new to Australia.
SMITH DJ and BROWN HE and TONGE JI and SINNAMON CN and MACDONALD VM and ROSS CJ and DOHERTY RL
PubMed: 13159738
05/1954

Epidemiological observations on leptospirosis in North Queensland.
DERRICK EH and GORDON D and ROSS CJ and DOHERTY RL and SINNAMON CN and MACDONALD VM and KENNEDY JM
PubMed: 13159737
05/1954

Rocky Mountain spotted fever; case report and discussion of therapy.
GRAHAM GS and ROSS CJ
PubMed: 20285376
03/1947

Research

Canadian Pharmacogenomic Network for Drug Safety (CPNDS)
Canadian Institutes for Health Research (CIHR), Canada Foundation for Innovation (CFI), Genome British Columbia

The goal of CPNDS is to prevent adverse drug reactions (ADRs) in childhood by identifying predictive genomic markers for specific ADRs. Within five years, CPNDS intends to incorporate these markers into diagnostic tools that will be used to predict and prevent ADRs in children through specific dosing recommendations for commonly used drugs based on an individual's genetic make-up. The long-term goal for this project is to develop a user-friendly, and effective ADR monitoring tool and national database, to proactively prevent adverse drug reactions in susceptible children.

Specific projects seek to identify the key causal genetic factors of serious ADRs in children, including severe hearing loss caused by cisplatin chemotherapy; a lethal reaction to codeine in newborns and young children, anthracycline-induced heart failure, vincristine-induced peripheral neurotoxicity and drug-induced severe rash.

Grants

Pharmacogenetics of Warfarin Safety and Effectiveness in Children Canadian – CIHR (2012-2013)

Champions of Genetics New Investigator Award: Drug Safety Pharmacogenomics Evaluation (SAPHE) Initiative - Canadian Gene Cure Foundation (2012-2014)

Identification of pharmacogenomic variants for the prevention of vincristine-induced neurotoxicity – CIHR (2013-2014)

Honours & Awards

2012 - New Investigator Award, Canadian Institutes of Health Research

Research Group Members

Britt Drogemoller, Post Doctoral Fellow
Kristen Gibson, Graduate Research Assistant
Erandika Prasadani Gunaretnam, Research Technician
Xiaohua Han
Jafar Hasbullah, Graduate Student
Neel Mehta, Postdoctoral Fellow
Fudan Miao
Erika Scott, Graduate Student
Galen Wright, Research Associate
Lin-hua Zhang
Steven Zhou, Research Assistant